From the Editor-in-Chief’s Desk: Improving the Health of Children with Greater Rigor in the Clinical Science of Psychopharmacology

Abstract

Get full access to this article

View all access options for this article.

References

Chu

, Ince

. Letter: Collaborating with applied behavior analysis teams to optimize telehealth pharmacologic management of catatonia in nonverbal youth with autism spectrum disorder. J Child Adolesc Psychopharmacol, 2025; 35(6):365–368; doi: 10.1089/cap.2025.0021

Ferguson

, Dovgan

, Hoffman

, et al. Pilot trial on the effects of propranolol on gastrointestinal symptoms in autism spectrum disorder and heart rate variability as a treatment response biomarker. J Child Adolesc Psychopharmacol, 2025; 35(6):359–364; doi: 10.1089/cap.2024.0002

Harris

, Fosdick

, Zappia

, et al. Safety and effectiveness of clozapine in youth and young adults with neurodevelopmental disorders and severe, treatment-refractory irritability and aggression: A retrospective chart review. J Child Adolesc Psychopharmacol, 2025; 35(6):337–346; doi: 10.1089/cap.2024.0104

Kumpf

, Hughes

, Bloch

. Letter: Food and drug administration clearance of transcranial magnetic stimulation for adolescent depression in the absence of data supporting efficacy. J Child Adolesc Psychopharmacol, 2025; 35(6):369–371; doi: 10.1089/cap.2024.0142

Mills

, Strawn

. Myths of randomized controlled trial analysis in pediatric psychopharmacology. J Child Adolesc Psychopharmacol, 2025; 35(5):263–268; doi: 10.1089/cap.2025.0005

Pimenta de Figueiredo

, de Almeida

, de Freitas

FAC

, et al. Beyond the off-label: A systematic review of what we know about clozapine use for children. J Child Adolesc Psychopharmacol, 2024; 34(9):e419–e426; doi: 10.1089/cap.2024.0070

Ramaker

, Kolitsopoulos

, Ludwig

, et al. Safety outcomes from a long-term, prospective study of sertraline use in children and adolescents: The sertraline pediatric registry for the evaluation of safety. J Child Adolesc Psychopharmacol, 2025; 35(6):326–336; doi: 10.1089/cap.2024.0054

Roy

, Colacicco

, Frigeri

, et al. Definition of response in randomized controlled trials of medications for attention-deficit/hyperactivity disorder across the lifespan: A systematic review. J Child Adolesc Psychopharmacol, 2025; 35(6):321–325; doi: 10.1089/cap.2025.0029

Scheeringa

. False positives for Criterion A trauma events and posttraumatic stress disorder symptoms with questionnaires are common in children and adolescents and could not be eliminated with enhanced instructions. J Child Adolesc Psychopharmacol, 2025; 35(6):347–352; doi: 10.1089/cap.2024.0126

10.

Singh

. Editorial: Placebo response in child and adolescent psychiatry: To mitigate or to harness? J Am Acad Child Adolesc Psychiatry, 2025; 64(5):550–555; doi: 10.1016/j.jaac.2025.01.024

11.

Thom

, Warren

, Khan

, et al. Blueprint for translational precision medicine in autism spectrum disorder and related neurogenetic syndromes. J Child Adolesc Psychopharmacol, 2025; 35(4):178–193; doi: 10.1089/cap.2025.0023

12.

Wilson

, Wong

. SPTAN1—results of a caregiver survey. J Child Adolesc Psychopharmacol, 2025; 35(6):353–358; doi: 10.1089/cap.2024.0100